Status and phase
Conditions
Treatments
About
The purpose of this study is to determine if the addition of a unique targeted agent called Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard treatment with chemotherapy and radiation.
Full description
This research study involves the use of a combination of two chemotherapies, cisplatin and docetaxel, which have been known to shrink head and neck cancers and are a commonly used treatment for this type of cancer. This combination will then be followed by radiation and more chemotherapy.
The purpose of this study is to see whether this combination of chemotherapy and radiation, with the addition of Cetuximab, can improve control of disease and collect information on what side effects this combination therapy may have. In addition, biologic factors (markers) will be studied that may help to predict and treat head and neck cancer patients in the future.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
39 participants in 1 patient group
There are currently no registered sites for this trial.
Start date
Oct 01, 2005 • 19 years ago
End date
Jul 01, 2013 • 11 years ago
Results posted
ViewJul 11, 2017 • 7 years ago
Today
Jan 22, 2025
Lead Sponsor
Collaborating Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal